The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), which made more than $1 billion in sales last year, and recently ...

where J&J also presented new data on its treatment-resistant depression (TRD and MDD therapy Spravato (esketamine). “In MDD, insomnia symptoms exacerbate the risk of depressive relapse ...

Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...

Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...

While VRET therapy is still evolving, its potential to revolutionize mental health care could play a transformative role in ...

A study published March 17 in JAMA Network Open found that transgender, nonbinary and gender-diverse people who were ...

Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care.

This FDA clearance for the Magstim Horizon 3.0 and Inspire systems builds on the existing patient TMS clearances for adult patients, making it possible for physicians and nurse practitioners to treat ...